Episodic Migraine
Conditions
Brief summary
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
Interventions
DRUGEptinezumab
Solution for infusion
DRUGPlacebo
Solution for infusion
Sponsors
H. Lundbeck A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3; in the opinion of the investigator) with history of migraine headaches of at least 6 months prior to the Screening Visit. * During the 28-day screening period, the participant (and their parent/caregiver, when applicable) must adequately complete the headache eDiary (≥23 of the 28 days) following the day of the Screening Visit. * During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migraine days as documented in the eDiary.
Exclusion criteria
* History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes (previously referred to as complicated migraine), such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, recurrent painful ophthalmic neuropathy, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration, e.g., \>60 min). * History of moderate or severe head trauma or other neurological disorder or systemic medical disease that is, in the investigator's opinion, likely to affect the functions of the central nervous system. * Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania are excluded. * Any other disorder for which the treatment takes priority over treatment of migraine or is likely to interfere with study treatment or impair treatment compliance. Other inclusion and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12 | Baseline, Weeks 1-12 |
Secondary
| Measure | Time frame |
|---|---|
| Response: ≥50% Reduction From Baseline in MMDs | Baseline, Weeks 1-4 and Weeks 1-12 |
| Percentage of Participants with Migraine on the Day After Dosing (Day 1) | On Day After Dosing |
| Change From Baseline in MMDs with Acute Medication Use | Baseline, Weeks 1-12 |
| Response: ≥75% reduction from baseline in MMDs | Baseline, Weeks 1-4 and Weeks 1-12 |
| Change From Baseline in the Number of Monthly Headache Days (MHDs) | Baseline, Weeks 1-12 |
| Change From Baseline in Monthly Hours with Headache | Baseline, Weeks 1-12 |
| Change From Baseline in Days with Acute Medication | Baseline, Weeks 1-12 |
| Change From Baseline in Rate of Migraines with Severe Pain Intensity | Baseline, Weeks 1-12 |
| Change From Baseline to Week 12 in Pediatric Migraine Disability Assessment (PedMIDAS) Score | Baseline, Week 12 |
| Free Eptinezumab Plasma Concentrations | Day 0 (pre-dose) and at Weeks 8, 12, and 20 |
| Number of Participants With Specific Anti-eptinezumab Antibodies (Anti-Drug Antibodies [ADA]) | Day 0 (pre-dose) and at Weeks 8, 12, and 20 |
| Number of Participants With Specific ADA-Positive Samples for Neutralizing Antibodies (NAb) | Day 0 (pre-dose) and at Weeks 8, 12, and 20 |
Countries
Argentina, Canada, Italy, Mexico, Poland, Portugal, Serbia, Spain, Turkey (Türkiye), United Kingdom, United States
Contacts
CONTACTEmail contact via H. Lundbeck A/S
STUDY_DIRECTOREmail contact via H. Lundbeck A/S
HQ_Medinfo@Lundbeck.com
Outcome results
None listed